Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib

BACKGROUND: Sorafenib, a multi-target kinase inhibitor, inhibits members of the MAPK pathway and receptor tyrosine kinases, including VEGF-R2. Sorafenib, carboplatin and paclitaxel (SCP) has anti-tumor activity in melanoma patients, but no association was found between response and activating B-Raf(...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Jilaveanu, Lucia, Zito, Christopher, Lee, Sandra J., Nathanson, Katherine L., Camp, Robert L., Rimm, David L., Flaherty, Keith T., Kluger, Harriet M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4263281/
https://ncbi.nlm.nih.gov/pubmed/19188183
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-2280
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak